Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TriSalus Life Sciences ( (TLSI) ) just unveiled an announcement.
On February 19, 2026, TriSalus Life Sciences, Inc. entered into an underwriting agreement with Lake Street Capital Markets for a public offering of 9,756,100 shares of common stock at $4.10 per share, with an additional 30-day option for underwriters to buy up to 1,463,415 more shares to cover over-allotments. The deal includes a 6% underwriting discount, reimbursement of certain expenses, 90-day lock-ups for the company and key insiders, and is expected to close around February 23, 2026, subject to customary conditions.
TriSalus expects to raise approximately $37.0 million in net proceeds from the base offering, or about $42.64 million if the over-allotment option is fully exercised, and plans to use the funds for general corporate purposes, including capital expenditures, working capital, and administrative costs. The shares are being issued under an effective shelf registration, and the capital raise supports the company’s ongoing development and commercialization efforts in oncology-focused medical technologies and its investigational immunotherapy programs.
On February 19, 2026, the company announced its intention to conduct the underwritten public offering, followed by a February 20, 2026 press release disclosing the pricing of the transaction. Lake Street Capital Markets is acting as the sole book-runner, reinforcing TriSalus’s access to public equity markets as it advances its Pressure-Enabled Drug Delivery platform and related clinical programs aimed at improving treatment for solid tumor patients.
The most recent analyst rating on (TLSI) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on TriSalus Life Sciences stock, see the TLSI Stock Forecast page.
Spark’s Take on TLSI Stock
According to Spark, TipRanks’ AI Analyst, TLSI is a Neutral.
TriSalus Life Sciences’ overall stock score is driven by significant financial challenges, including persistent losses and a weak balance sheet, which weigh heavily on the score. However, strong technical indicators and positive earnings call sentiment, highlighting revenue growth and strategic expansion, provide some optimism. The negative P/E ratio and lack of dividend yield further constrain the valuation score.
To see Spark’s full report on TLSI stock, click here.
More about TriSalus Life Sciences
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that develops novel drug delivery technologies and investigational immunotherapies to improve outcomes for patients with solid tumors. Its platform combines proprietary Pressure-Enabled Drug Delivery devices, including the FDA-cleared TriNav Infusion Systems for liver tumors and a pancreatic infusion system, with its clinical-stage TLR9 agonist nelitolimod for liver and pancreatic cancer settings.
The company’s PEDD technology is designed to modulate pressure and flow to deliver more therapeutics directly to tumors while limiting exposure to healthy tissue, supporting its Pressure-Enabled Regional Immuno-Oncology clinical strategy. TriSalus is in the final stages of data completion for several phase 1 trials and plans to explore partnership opportunities to advance development of nelitolimod and its integrated technology platform.
Average Trading Volume: 162,374
Technical Sentiment Signal: Sell
Current Market Cap: $231.8M
Learn more about TLSI stock on TipRanks’ Stock Analysis page.